Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Exclusive Breastfeeding and the Risk of Postpartum Relapses in Women with Multiple Sclerosis
Arch Neurol 66:958-963, Langer-Gould,A.,et al, 2009
Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005
Pregnancy, Delivery, and Birth Outcome in Women with Multiple Sclerosis
Neurol 65:1961-1963, Dahl,J.,et al, 2005
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Intravenous Immunoglobulin Treatment in Multiple Sclerosis, Effect on Relapses
Neurol 50:398-402, Achiron,A.,et al, 1998
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
NEJM 339:285-291, 3391998., Confavreux,C.,et al, 1998
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Magnetic Resonance Evaluation of Disease Activity During Pregnancy in Multiple Sclerosis
Neurol 44:327-329, vanWalderveen,M.A.A.,et al, 1994
Fecal Incontinence
NEJM 326:1002-1007, Madoff,R.D.,et al, 1992
The Clinical Course of Multiple Sclerosis During Pregnancy and the Puerperium
Arch Neurol 47:738-742, Birk,K.,et al, 1990
The Influence of Pregnancy on Disability From Multiple Sclerosis:A Population in Middlesex County, Ontario
Neurol 39:1438-1440, Weinshenker,B.G.,et al, 1989
Pregnancy and Multiple Sclerosis
JNNP 51:495-498, Frith,J.A.&McLeod,J.G., 1988
Risk of Multiple Sclerosis Exacerbation During Pregnancy and Breast-Feeding
JAMA 259:3441-3443, Nelson,L.M.,et al, 1988
Pregnancy & Multiple Sclerosis
Arch Neurol 43:719-726, Birk,K.,et al, 1986
The Effects of Pregnancy in Multiple Sclerosis:A Retrospective Study
Neurol 36:1097-1098, Thompson,D.S.,et al, 1986
Activity of Multiple Sclerosis During Pregnancy & Puerperium
Ann Neurol 16:229-231, Korn-Lubetzki,I.,et al, 1984
Surgical Lesions Misdiagnosed as Multiple Sclerosis-Indication for Contrast Study
Milit Med 141:378, Finelli,P.F., 1976
Association of Changes in Activity Patterns with Brain Atrophy and Disability Progression in People with Multiple Sclerosis
Neurol 106:e214678, e214742, Fitzgerald,K.C.,et al, 2026
Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis
Neurol 106:e214794, Sosa,S.M.,et al, 2026
Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome
JAMA Neurol 83:250-258, Lim,T.R.et al, 2026
Frequency of AQP4 and MOG Antibodies in Patients with Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria
Neurol 106:e214753, Deschamps,R.,et al, 2026
The 2024 McDonld Criteria for Dignosis of Multiple Sclerosis, The Rubber meets the Road
Neurol 106:e214688, Miller, A.E., 2026
Diagnostic Value of the Kappa Free light Chain Index to Distinguish MOGAD, NMOSD, and MS
Neurol 106:e214946, Tournier,A.,et al, 2026
Using Susceptibility-Based Imaging in highly ctive Late-Onset Multiple Sclerosis
Neurol 106:e214794, Sosa,S.M.,et al, 2026
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic
Neurol 105:e213912, Remner,B.,et al, 2025
Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria
Lancet Neurol 24:850-865, Montalban,X.,et al, 2025
A 30-Year-Old Female Patient with Multiple Sclerosis Presenting with Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia
Neurol 105:e214429, Trentadue,T.,et al, 2025
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis
Ann Neurol 96:846-854, Marrodan,M.,et al, 2024
Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease
Ann Neurol 96:1086-1091, Fadda,G.,et al, 2024
Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis
Neurol 100:47-48, Murphy,O.C. et al, 2023
Differentiating Multiple Sclerosis from AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease with Imaging
Neurol 100:e308-e323, Cortesa,R.,et al, 2023
Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder
Neurol 100:e1418-e1432, Cacciaguerra, L.,et al, 2023
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023
Overlapping Anti-NMDAR Encephalitis and Multiple Sclerosis: A Case Report and Literature Review
Front Immunol doi:10.3389/Fimmun.2023.1088801, Liu,P.,et al, 2023
Kappa Free Light Chain Biomarkers are Efficient for the Diagnosis of Multiple Sclerosis
Neurol Neuroinflamm 10:e200049, Levraut,M.,et al, 2023
Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis
Neurol 97:e414-e422, Jolliffe, E.A.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020